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INTRODUCTION
Multiple myeloma (MM) is a neoplasm of plasma cells and
is responsible for about 1% of all malignant neoplasms and
about 13% of hematologic malignancies (1). The most com-
mon immunologic subtype of MM is immunoglobulin (Ig)
G, followed by IgA and light-chain only. In comparison,
IgD MM, which was first recognized by Rowe and Fahey
(2), affects less than 2% of all patient with MM (3). It is
known to have a more aggressive clinical behavior than other
subtypes of MM and is associated with relatively high fre-
quencies of renal failure, extramedullary involvement, hyper-
calcemia, amyloidosis, and Bence-Jones proteinuria, as well
as a short survival period (4-7).
When compared with standard-dose chemotherapy for
MM, high-dose chemotherapy in combination with autolo-
gous stem cell transplantation (ASCT) has been shown to
significantly improve rates of complete remission (CR), CR
duration, event-free survival (EFS), and overall survival (OS)
(8-10). Recently, it was shown that outcomes of ASCT are
superior to those of standard-dose chemotherapy in a series
of 25 patients with IgD MM (11). However, few studies have
compared the response to ASCT of patients with different
MM subtypes (12, 13).
We have retrospectively analyzed 77 patients with MM
who underwent ASCT in our center. The aim of our analy-
sis was to evaluate EFS and OS after ASCT in patients with
different MM subtypes. 
MATERIALS AND METHODS 
Patients
Between November 1998 and January 2005, a total of 77
patients with MM were treated with ASCT at the Asan Med-
ical Center. All patients had adequate stem cell collection
and met all the eligibility criteria of the ASCT protocol includ-
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Poor Outcomes for IgD Multiple Myeloma Patients Following 
High-Dose Melphalan and Autologous Stem Cell Transplantation: 
A Single Center Experience
Immunoglobulin (Ig) D multiple myeloma (MM) accounts for 2% of all MM cases
and has been reported to be associated with poor prognosis compared with other
MM subtypes. The aim of the present study was to compare the effects of high-dose
melphalan treatment and autologous stem cell transplantation (ASCT) on the sur-
vival of patients with IgD MM and patients with other MM subtypes. Between Novem-
ber 1998 and January 2005, a total of 77 patients with MM who underwent ASCT
at the Asan Medical Center were enrolled in this study. High-dose melphalan (total
200 mg/m
2) was used as high-dose chemotherapy. The study population was divid-
ed into two groups based on MM subtype: those with IgD MM; and those with other
MM subtypes. A total of 8 patients with IgD MM were identified, accounting for about
10% of the study population. Thirty-six patients (47%) had IgG MM, 17 patients
(22%) had IgA MM, and 16 patients (20%) had free light-chain MM. The two groups
were similar in baseline characteristics. The median follow-up was 17 months and
the median overall survival (OS) was 39 months. In the IgD MM group, median event-
free survival (EFS) and OS were 6.9 and 12 months, respectively. In the patients
with other MM subtypes, median EFS and OS were 11.5 and 55.5 months (p=0.01,
p<0.01), respectively. Multivariate analysis of all patients identified IgD subtype
(p=0.002) and Southwest Oncology Group (SWOG) stage 2 or greater at the time
of ASCT (p=0.01) as adverse prognostic factors for survival. In this small study at
a single center in Korea, patients with IgD MM had poorer outcomes after ASCT
than did patients with other MM subtypes. 
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Accepted : 29 January 2008ing age ≤70 yr and adequate cardiopulmonary and hepatic
functions. At study entry, the exclusion criterion was poor
performance status, as shown by an Eastern Cooperative
Oncology Group (ECOG) score≥3. All patients gave in-
formed consent.
The study population was divided into two groups based
on MM subtype: patients with IgD MM (8 patients); and
those with other MM subtypes (69 patients). 
Prior to ASCT, patients had received one to two lines of
treatment, while 88% of the cases had received only one regi-
men of chemotherapy. Most patients were treated with VAD
(vincristine, adriamycin, and dexamethasone) (67 patients,
87%) or VAD like regimen (6 patients, 8%), while four
patients (5%) had received MP (melphalan, prednisone) as
first-line treatment. At the time of transplant, 22% of patients
were in CR. The vast majority had achieved a partial response
(PR) with previous chemotherapy regimens, while 7 (9%) of
them had stable disease. The median time interval between
diagnosis and transplant was 5.6 months (range: 1.8-83.5
months). Of the patients, 13 (16.9%) had a second trans-
plant; 4 of these had a planned second ASCT in CR and 9
were autografted after relapse or progression of their disease. 
Treatment protocol 
Peripheral blood stem cells were collected during 1-3 con-
secutive leukaphereses, following high-dose cyclophosphamide
4 g/m2, i.v., with subsequent lenograstim at 10 μ g/kg/day
from day 3 to the last day of leukapheresis. The concentura-
tion of circulating peripheral blood hematopoietic progenitor
cells (HPCs) were monitored daily, and when HPCs become
5 cells/μ L, autologous stem cell harvest was performed (14).
Peripheral blood stem cell were harvested with a target con-
centration of 10.0×106 CD34+ cells/kg.
High-dose chemotherapy was performed 3 and 2 days
before stem cells infusion (day -3 and day -2). High-dose
chemotherapy comprised melphalan 100 mg/m2 iv infusion
for 30 min on each of theses two consecutive days (total 200
mg/m2). Stem cells were infused on day 0. Subcutaneous
lenograstim treatment 5 μ g/kg/day was started on day 1 and
continued until the absolute neutrophil count was measured
as ≥1,000 cells/μ L on two consecutive days. The second
ASCT was performed within 3-9 months of the first ASCT
in all patients who had second ASCT except one, for whom
the interval was 4 yr. The second ASCT was performed fol-
lowing the same procedure as the first ASCT. 
Staging and response criteria 
At the time of ASCT, staging was performed according to
the Southwest Oncology Group (SWOG) staging system
(15) and the 2005 International Staging Sytem (ISS) guide-
lines (16). The European Group for Blood and Marrow Trans-
plant (EMBT) criteria were modified for assessing disease
response (17). CR was defined as absence of monoclonal Ig
from the serum and/or urine as shown by immuno-fixation
analysis and less than 5% plasma cells on bone marrow aspi-
rate (and biopsies, if performed). Patients were considered
to be in PR if there was at least a 50% reduction in the serum
M-protein concentration and a reduction in the level of Bence-
Jones proteinuria by greater than 75% reduction or to less
than 0.2 g/24 hr. No change was defined as no change or a
reduction in paraprotein levels of less than 50%. Progressive
disease (PD) was defined as a confirmed >25% increase in
the serum paraprotein concentration compared with the level
at the time of the best response, an increase in Bence-Jones
proteinuria to more than 1.0 g/24 hr, or other unequivocal
signs of disease progression, such as hypercalcemia, progres-
sive skeletal disease, or soft tissue plasmacytoma. Relapse was
defined as the reappearance of paraprotein in the serum of
patients who achieved CR and an increase of greater than
25% in the serum paraprotein concentration, or other unequiv-
ocal signs of disease progression such as hypercalcemia or
the development of new extramedullary disease for patients
who did not achieve CR. Patients were considered to be in
continued CR or continued PR if the CR/PR status attained
after the induction chemotherapy was continued after ASCT.
Evaluation and follow-up
Patient responses were first evaluated 4 weeks after ASCT.
Protein electrophoresis and immuno-fixation analyses of
serum and/or urine were performed. If CR was achieved, the
patient was evaluated every month for the first 2 months,
then three times at 2 month intervals, and every three months
thereafter. If CR was not achieved initially, the patient was
evaluated every month until CR was achieved. At each fol-
low-up visit, the patient’s clinical history was recorded and
he or she underwent a physical examination, complete blood
count, platelet count, and liver function tests, and serum
and/or urine protein electrophoresis analyses. If relapse or
progression was confirmed, the decision of whether to per-
form further therapy was at the discretion of the participat-
ing physicians.
Statistical analysis
The proportions of patients with a given characteristic
were compared with the use of  2 test or Fisher’s exact test.
Differences in continuous variables were analyzed with the
Student’s t-test and confirmed with the use of the Mann-
Whitney U test. All tests were two-tailed. An event was
defined as progression, relapse, or death due to any cause.
EFS was calculated for all patients from the date of ASCT.
OS was calculated from the date of ASCT to death of the
patient or to the date the patient was last known to be alive.
Kaplan-Meier curves for EFS and OS were plotted and com-
pared using the log-rank test. Prognostic factors for survival
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model for multivariate analysis, which was performed for
significant univariate variables. A p value <0.05 was consid-
ered significant. All calculations were performed using SPSS
version 12.0 for Windows (SPSS Inc., Chicago, IL, U.S.A.).
RESULTS
Patient characteristics
A total of 8 patients with IgD MM were identified, account-
ing for about 10% of the study population. In this study,
36 patients (47%) had IgG MM, 17 patients (22%) had Ig
A MM, and 16 patients (21%) had free light-chain MM. 
Table 1 shows the base-line characteristics of the 77 patients.
The median age of the patients was 51.0 yr (range, 20-68
yr). There were no significant differences in patient charac-
teristics at baseline between the two groups (those with IgD
MM vs. those with other MM subtypes). The two groups
were specially similar in lines of prior chemotherapy, inter-
val from diagnosis to ASCT, disease status prior to ASCT,
and the proportion of patients who had second ASCT, which
could have influence on outcomes following ASCT. Forty
patients were checked for cytogenetic abnormalities, of whom
24 patients (60%) showed abnormalities. Nine patients had
chromosome 13 deletion or hypodiploidy both of which are
known to be poor prognostic factors (18). 
Treatment-related toxicity
The treatment-related mortality (TRM) was 3% (2/69
patients) in the group of patient with other MM subtypes.
The cause of death was septicemia. There was no treatment-
related mortality in the IgD MM group. No patient devel-
oped grade III-IV cardiac, pulmonary, renal or liver toxicity
(World Health Organization scale), whereas neutropenic
fever was present in almost all patients and severe mucositis
was observed in a third of the patients.
Response rate
Table 2 shows the patient responses to ASCT. The overall
response rate (CR and PR) was 96%. Specifically, the CR
rate was 75% for patients with IgD MM, compared with
58% for patients with other MM subtypes (p=0.81). In the
IgD MM group, 5 patients (63%) were in continued CR/PR.
In the group of patient with other MM subtypes, 37 patients
(54%) were in continued CR/PR.
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IgD MM 
(%)
Other Ig sub-
types MM (%)
Number of patient 8 69
Age (range) 45.5 (33-61) 53.0 (20-68)
Gender
Male 5 (62.5) 38 (55.1)
Female 3 (37.5) 31 (44.9)
Cycles of prior chemotherapy 4 (3-5) 3 (2-31) 
Lines of prior chemotherapy
1 6 (75) 62 (89.9)
≥2 2 (25) 7 (10.1)
Interval (months) from diagnosis  5.2 (4.2-9.1) 5.6 (1.8-83.5)
to ASCT
Disease status prior to ASCT
CR 3 (37.5) 14 (20.3)
PR 5 (62.5) 48 (69.6)
No change/progressive disease - 7 (10.1)
SWOG stage
I 2 (25.0) 21 (30.4)
II 5 (32.5) 37 (53.6)
III 1 (15.6) 10 (14.5)
IV - 1 (1.4)
ISS stage
I   5 (62.5) 35 (50.7)
II 2 (25.0) 23 (33.3)
III 1 (12.5) 11 (15.9)
Performance status (ECOG)
0 2 (25) 14 (20.3)
1 6 (75) 52 (75.4)
2 - 3 (4.3)
Hemoglobin (g/dL) (range) 10.9 (8.6-11.9) 10.4 (7.7-13.8)
Creatinine (mg/dL) (range) 1.1 (0.7-1.6) 0.8 (0.4-11.2)
Calcium (mg/dL) (range) 8.7 (7.9-9.3) 8.9 (7.3-9.9)
Albumin (g/dL) (range) 4.0 (2.9-5.2) 3.7 (1.8-4.5)
β 2-microglobulin (μ g/mL) (range) 2.9 (1.9-19.0) 2.8 (1.0-27.6)
Cytogenetics prior to ASCT
No abnormalities 2 (25) 14 (20.3)
Chr. 13 deletion or hypodiploidy 1 (12.5) 8 (11.6)
Other abnormalities 2 (25) 13 (18.8)
Untested/unknown 3 (37.5) 34 (49.3)
Second ASCT  1 (12.5) 12 (17.4)
Table 1. Patient characteristics at the time of ASCT according to
MM subtype*
ASCT indicates autologous stem cell transplantation.
ASCT, autologous stem cell transplantation; Ig, immunoglobulin; MM,
multiple myeloma; CR, complete remission; PR, partial response;
SWOG, Southwest Oncology Group; ISS, International Staging System;
ECOG, Eastern Cooperative Oncology Group; Chr., Chromosome.
*, Median (range) or number of patients (%).
ASCT indicates autologous stem cell transplantation.
MM, multiple myeloma; ASCT, autologous stem cell transplantation.
IgD MM (%)
(N=8)
Other Ig subtypes
MM (%) (N=69)
Best response to ASCT
Complete response 6 (75) 40 (58.0)
Partial response 2 (25) 27 (39.1)
No change - 1 (1.4)
Progressive disease - 1 (1.4)
Table 2. Response rates after ASCT according to MM subtypeEFS and OS after ASCT
In this study population, the median follow-up was 17.2
months and the median OS was 39.3 months. In the IgD
MM group, the median follow-up was 17.1 months (range,
4.7 to 29.7) from the time of ASCT. The median EFS and
OS were 6.9 and 12.0 months, respectively. Of the 6 deaths
in this group, all were attributed to MM. In the group of
patient with other MM subtypes, the median follow-up was
17.2 months (range, 1.1 to 71.3) from the time of ASCT.
The median EFS and OS were 11.5 and 55.5 months, respec-
tively. Of the 21 deaths in this group, 13 were attributed to
MM, 7 to infection, and 1 to suicide. Patients in the IgD
MM group had significantly shorter EFS (p=0.01) (Fig. 1)
and OS (p<0.01) (Fig. 2) compared with patients with other
MM subtypes. There were no significant differences in OS
and EFS among patients with other MM subtypes (p=0.7 and
p=0.9, respectively). The median OS in other MM subtypes
was 62.6, 40.0, and 55.5 months, and the EFS was 10.6, 11.2,
and 15.0 months for IgG, IgA, and free light chain subtype,
respectively. 
In patients with chromosome 13 deletion or hypodiploidy,
the median OS was 39.3 months. 
Factors associated with EFS and OS following ASCT
In this study population, age, performance status, lines of
prior chemotherapy, interval from diagnosis to ASCT, hemo-
globin, creatinine, and albumin levels at the time of ASCT,
and response after ASCT showed no association with either
EFS or OS. However, the level of β 2-microglobulin at the
time of ASCT was significantly associated with EFS and OS. 
OS after ASCT was associated with the SWOG stage at the
time of ASCT. The median OS was 62.6 months in patients
with SWOG stage 1, 24.5 months in patients with SWOG
stage 2, and 31.9 months in patients with SWOG stage 3.
In this study, patients with SWOG stage 1 had longer EFS
and OS compared with patients with SWOG stage 2 or
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Fig. 1. Event-free survival after ASCT.
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Fig. 2. Overall survival after ASCT.
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End point Parameter p value Relative risk 95% CI
OS IgD subtype 0.002 4.625 1.8-12.1
SWOG stage 1 0.010 0.241 0.08-0.71
EFS IgD subtype 0.023 2.587 1.1-5.9
Table 4. Prognostic factors for survival: multivariate analysis
CR indicates complete response. 
EFS, event-free survival; OS, overall survival; ASCT, autologous stem
cell transplantation; ISS, International staging system; SWOG, South-
west Oncology Group; CR, complete remission; PR, partial response.
CI, confidence interval; OS, overall survival; EFS, event-free survival. 
EFS
(p value)
OS
(p value)
Gender (male vs. female) 0.995 0.476
Age at ASCT (<60 yr vs. others) 0.225 0.496
Ig type (IgD vs. others) 0.016 0.002
Lines of prior chemotherapy (<2 vs. ≥2) 0.392 0.417
Interval from diagnosis to ASCT (≤6 vs. >6 months) 0.071 0.075
ISS stage at ASCT (1 vs. 2+3) 0.766 0.096
SWOG stage at ASCT (1 vs. 2+3+4) 0.173 0.011
Performance status at ASCT (ECOG 0 vs. 1+2) 0.187 0.078
Hemoglobin at ASCT (<10.0 g/dL vs. ≥10.0 g/dL) 0.117 0.111
Creatinine at ASCT (<2 mg/dL vs. ≥2 mg/dL) 0.845 0.304
Albumin at ASCT (<3.0 g/dL vs. ≥3.0 g/dL) 0.840 0.398
β 2-microglobulin at ASCT (<5.5 mg/L vs. 0.043 0.014
≥5.5 mg/L)
Response after ASCT (CR vs. non-CR)  0.500 0.565
Table 3. Univariate analysisgreater (p=0.173 and p=0.011, respectively).
The median OS was 62.6 months in patients with ISS
stage 1, 37.8 months in patients with ISS stage 2, and 23.1
months in patients with ISS stage 3. Differences in EFS and
OS among patients with different ISS clinical stages at the
time of ASCT were not statistically significant (p=0.78 and
p=0.185, respectively). 
The results of univariate analysis are summarized in Table
3. Statistically significant prognostic factors for OS in the
univariate analyses were SWOG stage 1, IgD subtype, and
β 2-microglobulin, whereas the prognostic factors for EFS
were only IgD subtype and β 2-microglobulin. The results of
multivariate analyses are presented in Table 4. Based on the
results of multivariate analyses, the prognostic factors asso-
ciated with significantly shorter OS were IgD subtype (p=
0.002) and SWOG stage 2 or greater at the time of ASCT
(p=0.01), whereas the prognostic factor associated with shorter
EFS was only IgD subtype (p=0.023).
DISCUSSION
We found that patients with IgD MM had significantly
shorter survival after ASCT compared with patients with
other MM subtypes (relative risk: 4.6; p=0.002). However,
the initial response to high dose chemotherapy and ASCT
was similar in patients with IgD MM and patients with other
MM subtypes. The overall response rate (CR and PR) follow-
ing ASCT was 100% in the IgD MM group and 97% in
patients with other MM subtypes, similar to that reported
from other studies (9, 12, 13, 19). However, patients with
IgD MM experienced earlier relapse/progression. The cumu-
lative incidence of relapse/progression at 1 yr was 85% in
patients with IgD MM and 51% in patients with other MM
subtypes (p=0.009). These results are in agreement with
those of previous studies comparing responses to conven-
tional chemotherapy and survival rates in patients with IgD
MM and patients with other MM subtypes (3, 4, 6, 7). 
Only 1-2% of all MM cases are of the IgD subtype (3). In
the present patient group, however, the frequency of IgD
MM was about 10%. Due to patients’ preference for our
hospital and referral bias, the spectrum of MM patients
treated at the Asan Medical Center was likely to be biased. 
The Durie-Salmon clinical stage at the time of ASCT does
not correlate well with prognosis (20), whereas the ISS stage
or SWOG stage at the time of ASCT do correlate well with
prognosis (15, 16). In addition, increased β 2-microglobulin
and reduced albumin levels immediately prior to ASCT are
known to be adverse prognostic factors (13, 19-21). In our
study, IgD subtype and SWOG stage at the time of ASCT
were found to be independently associated with OS after
ASCT. Although both the ISS and SWOG stage are based
on β 2-microglobulin and albumin levels, in this study the
SWOG stage seemed to be more useful for predicting prog-
nosis. Our study was not able to confirm the prognostic use
of cytogenetics because this information was only available
for 40 patients (52%). 
Most investigators consider IgD MM to be a particularly
aggressive subtype of MM, which affects younger patients,
has a high frequency of extramedullary involvement, and is
associated with renal function impairment, amyloidosis, and
a short survival period. However, few studies have compared
survival after ASCT for patients with MM of different sub-
types, and their results are inconsistent. Terpos et al. report-
ed that patients with non-secretory MM tend to experience
better outcomes than those with secretory MM (13), and
Sirohi et al. reported that patients with light chain MM had
a significantly shorter OS than did patients with IgG or IgA
MM (12). In those studies, however, only one patient had
IgD MM. In the present study, we found no significant dif-
ferences in OS and EFS among patients with other (non-IgD)
MM subtypes (p=0.7 and p=0.9, respectively). 
IgD subtype is associated with poor prognosis, so patients
with IgD MM need to be treated more aggressively. Advanced
stage IgD MM, according to SWOG or ISS staging systems,
could be treated with tandem ASCT, maintenance therapy
with thalidomide after ASCT or allogeneic stem cell trans-
plantation (22-25). 
This study had several potential limitations. First, this
was a retrospective study from a single center. Second, the
two groups were not matched due to the small number of
patients (especially IgD subtype). However, two groups were
similar in baseline characteristics. Despite these limitations,
this is the first report showing poor clinical outcomes after
ASCT for patients with IgD MM in Korea. 
In conclusion, the response to ASCT of patients with IgD
MM is similar to that of patients with other MM subtypes.
However, patients with IgD MM have poor survival rates
after ASCT compared with patients with other MM subtypes. 
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